At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 58 enrolled
Drug / intervention
Everolimus +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma
In Brief
A Phase 2 clinical trial evaluating Everolimus and Archival Tissue Analysis for Adult Diffuse Astrocytoma and 4 related conditions. Completed, enrolled 58 participants across 1 site.
Detailed Summary
This phase II trial studies how well everolimus works in treating patients with recurrent low-grade glioma. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Diffuse Astrocytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Subependymal Giant Cell Astrocytoma, Recurrent Adult Brain Neoplasm
CountriesUnited States
CollaboratorsNovartis
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2009
Enrollment StartJan 2009
Primary CompletionJun 2017
Study CompletionNov 2017
TodayJul 2026
First PostedJan 15, 2009
Enrollment StartJan 23, 2009
Primary CompletionJun 12, 2017
Study CompletionNov 13, 2017
TodayJul 2, 2026
Enrollment to primary: 8.4 yearsPosted 17.5 years ago
Interventions
Everolimusdrug
Given PO
Archival Tissue Analysisother
Correlative studies